CONEXEU SCIENCES INC
CNXUNASDAQTrading Snapshot
- Day Range
- $3.68 – $3.76
- 52-Week Range
- $3.69 – $18.79
- Volume
- $2.61B
- Avg Volume
- $2.88B
- Shares Outstanding
- 26.8M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $15M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own CNXU
- ✓High-growth profile — revenue up +55.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CONEXEU SCIENCES INC
CNXU
StockOtter · stockotter.spaceAbout CONEXEU SCIENCES INC
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
Conexeu Sciences Sets September and October 2026 Conference Schedule
RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, is ple
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform
The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.
/PRNewswire/ -- Equity Insider News Commentary - Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill
Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence